Table 1. Distribution of HCC patients’ characteristics and prognosis analysis.
| Variable | All patients, n (%) n = 492 | OS | RFS | ||||
|---|---|---|---|---|---|---|---|
| Death, n (%)n = 179 | HRa (95% CI) | P-value | Recurrence, n (%)n = 295 | HRa (95% CI) | P-value | ||
| Gender | |||||||
| Female | 67(13.6) | 20(11.2) | Ref. | 34(11.5) | Ref. | ||
| Male | 425(86.4) | 159(88.8) | 1.80(1.11–2.91) | 0.017 | 261(88.5) | 1.59(1.10–2.30) | 0.013 |
| Age | |||||||
| <53 | 253(51.4) | 93(52.0) | Ref. | 160(54.2) | Ref. | ||
| ≥53 | 239(48.6) | 86(48.0) | 1.19(0.88–1.61) | 0.267 | 135(45.8) | 1.00(0.79–1.27) | 0.972 |
| HBsAg | |||||||
| Negetive | 46(9.3) | 16(8.9) | Ref. | 27(9.2) | Ref. | ||
| Positve | 446(90.7) | 163(91.1) | 1.02(0.60–1.75) | 0.940 | 268(90.8) | 1.11(0.74–1.68) | 0.615 |
| Serum AFP | |||||||
| <200 | 264(53.7) | 68(38.0) | Ref. | 138(46.8) | Ref. | ||
| ≥200 | 228(46.3) | 111(62.0) | 2.08(1.51–2.86) | <0.001 | 157(53.2) | 1.48(1.16–1.89) | 0.002 |
| Differentiation | |||||||
| I+II | 147(29.9) | 28(15.6) | Ref. | 65(22.0) | Ref. | ||
| III+IV | 344(70.1) | 151(84.4) | 2.40(1.58–3.65) | <0.001 | 230(78.0) | 1.82(1.36–2.43) | <0.001 |
| TNM stage | |||||||
| I+II | 394(80.1) | 114(63.7) | Ref. | 215(72.9) | Ref. | ||
| III+IV | 98(19.9) | 65(26.3) | 3.06(2.22–4.22) | <0.001 | 80(27.1) | 2.26(1.72–2.98) | <0.001 |
| Treatment | |||||||
| Surgery | 307(62.4) | 114(63.7) | Ref. | 193(65.4) | Ref. | ||
| Genotype | 185(37.6) | 65(36.3) | 0.62(0.45–0.85) | 0.003 | 102(34.6) | 0.56(0.43–0.71) | <0.001 |
Abbreviations: CI, confidence interval; HR, hazard ratio.
aAdjusted for gender, age, HBsAg, AFP level, clinical stage, differentiation and treatment after surgery, where appropriate.
bSignificant P values (<0.05).